DRDavid J. Restrepo

David J. Restrepo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David J. Restrepo has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Two Small-Bowel Hemangiomas Presenting With Distinct Endoscopic Phenotypes: Mimicry of Dieulafoy Lesion Versus Submucosal Neoplasm

    by Simran Agarwal, Rujul Patel, Effa Zahid, Neelam Khetpal, David J. Restrepo, Fernando Castro-Pavia, Asad Ur Rahman

    Small-bowel hemangiomas are uncommon vascular tumors that may present with obscure gastrointestinal bleeding and are difficult to identify because of their submucosal origin. We report 2 cases of transfusion-dependent small-bowel bleeding caused by cavernous hemangiomas with distinct endoscopic phenotypes. In the first case, brisk bleeding without visible mucosal protuberance led to initial interpretation as a Dieulafoy lesion, delaying recognition of an underlying submucosal process until surgical resection. In the second case, erythematous nonbleeding pulsatile distal ileal nodules prompted suspicion for hemangioma and expedited surgery. These cases illustrate how subtle endoscopic features influence diagnostic interpretation, surgical referral, and definitive treatment.

  • Open Access

    Oil injection for cosmetic enhancement of the upper extremities: a case report and review of literature.

    by Andrea Sisti, Maria T. Huayllani, David J. Restrepo, Daniel Boczar, Oscar J. Manrique, Peter N. Broer, Shane A. Shapiro, Antonio J. Forte

    Here the authors report a case of complications occured after injection of a site enhancement oil in the upper extremity for cosmetic muscles' volume enhancement and a literature review on the topic. The medical and sports communities should be aware of the secondary effects of site enhancement oils use, which could bring to severe complications.


  • Open Access

    Disparities in Access to Autologous Breast Reconstruction

    by David J. Restrepo, Maria T. Huayllani, Daniel Boczar, Andrea Sisti, Minh-Doan T. Nguyen, Jordan J. Cochuyt, Aaron C. Spaulding, Brian D. Rinker, Galen Perdikis, Antonio J. Forte

    Background and objectives: This study aimed to determine if age, race, region, insurance, and comorbidities affect the type of breast reconstruction that patients receive. Materials and methods: This analysis used the Florida Inpatient Discharge Dataset from 1 January 2013 to 30 September 2017, which contains deidentified patient-level administrative data from all acute care hospitals in the state of Florida. We included female patients, diagnosed with breast cancer, who underwent mastectomy and a subsequent breast reconstruction. We performed an χ2 test and logistic regression in this analysis. Results: On the multivariable analysis, we found that age, race, patient region, insurance payer, and Elixhauser score were all variables that significantly affected the type of reconstruction that patients received. Our results show that African American (odds ratio (OR): 0.68, 95%CI: 0.58–0.78, p < 0.001) and Hispanic or Latino (OR: 0.82, 95%CI: 0.72–0.93, p = 0.003) patients have significantly lower odds of receiving implant reconstruction when compared to white patients. Patients with Medicare (OR: 1.57, 95%CI: 1.33–1.86, p < 0.001) had significantly higher odds and patients with Medicaid (OR: 0.61, 95%CI: 0.51–0.74, p < 0.001) had significantly lower odds of getting autologous reconstruction when compared to patients with commercial insurance. Conclusions: Our study demonstrated that, in the state of Florida over the past years, variables, such as race, region, insurance, and comorbidities, play an important role in choosing the reconstruction modality. More efforts are needed to eradicate disparities and give all patients, despite their race, insurance payer, or region, equal access to health care.


  • Open Access

    Postmastectomy Radiation Therapy (PMRT) before and after 2-Stage Expander-Implant Breast Reconstruction: A Systematic Review

    by Jeremie D. Oliver, Daniel Boczar, Maria T. Huayllani, David J. Restrepo, Andrea Sisti, Oscar J. Manrique, Peter Niclas Broer, Sarah McLaughlin, Brian D. Rinker, Antonio Jorge Forte

    Background: In those undergoing treatment for breast cancer, evidence has demonstrated a significant improvement in survival, and a reduction in the risk of local recurrence in patients who undergo postmastectomy radiation therapy (PMRT). There is uncertainty about the optimal timing of PMRT, whether it should be before or after tissue expander or permanent implant placement. This study aimed to summarize the data reported in the literature on the effect of the timing of PMRT, both preceding and following 2-stage expander-implant breast reconstruction (IBR), and to statistically analyze the impact of timing on infection rates and the need for explantation. Methods: A comprehensive systematic review of the literature was conducted using the PubMed/Medline, Ovid, and Cochrane databases without timeframe limitations. Articles included in the analysis were those reporting outcomes data of PMRT in IBR published from 2009 to 2017. Chi-square statistical analysis was performed to compare infection and explantation rates between the two subgroups at p < 0.05. Results: A total of 11 studies met the inclusion criteria for this study. These studies reported outcomes data for 1565 total 2-stage expander-IBR procedures, where PMRT was used (1145 before, and 420 after, implant placement). There was a statistically significant higher likelihood of infection following pre-implant placement PMRT (21.03%, p = 0.000079), compared to PMRT after implant placement (9.69%). There was no difference in the rate of explantation between pre-implant placement PMRT (12.93%) and postimplant placement PMRT (11.43%). Conclusion: This study suggests that patients receiving PMRT before implant placement in 2-stage expander–implant based reconstruction may have a higher risk of developing an infection.


  • Open Access

    Local Pro- and Anti-Coagulation Therapy in the Plastic Surgical Patient: A Literature Review of the Evidence and Clinical Applications

    by Jeremie D. Oliver, Emma P. DeLoughery, Nikita Gupta, Daniel Boczar, Andrea Sisti, Maria T. Huayllani, David J. Restrepo, Michael S. Hu, Antonio J. Forte

    The risks of systemic anti-coagulation or its reversal are well known but accepted as necessary under certain circumstances. However, particularly in the plastic surgical patient, systemic alteration to hemostasis is often unnecessary when local therapy could provide the needed adjustments. The aim of this review was to provide a summarized overview of the clinical applications of topical anti- and pro-coagulant therapy in plastic and reconstructive surgery. While not a robust field as of yet, local tranexamic acid (TXA) has shown promise in achieving hemostasis under various circumstances, hemostats are widely used to halt bleeding, and local anticoagulants such as heparin can improve flap survival. The main challenge to the advancement of local therapy is drug delivery. However, with increasingly promising innovations underway, the field will hopefully expand to the betterment of patient care.